Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1

Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1 Curr Oncol Rep (2017) 19:64 DOI 10.1007/s11912-017-0627-0 BREAST CANCER (B OVERMOYER, SECTION EDITOR) Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1 1,2,3 1,2,3 François Bertucci & Anthony Gonçalves Springer Science+Business Media, LLC 2017 Abstract Introduction Purpose of Review The purpose of the review is to summarize the data regarding PD-L1 expression in breast cancer and the Despite considerable progresses over the past three decades, results of first clinical trials with PD-1 or PD-L1 inhibitors in 15% of patients with breast cancer still develop metastases patients with metastatic breast cancer. and die. Improved understanding of mammary oncogenesis Recent Findings PD-L1 expression is heterogeneous across has led to major therapeutic advances with the approval of primary breast cancers, and is generally associated with the several drugs targeting cancer cells. Examples include hor- presence of tumor-infiltrating lymphocytes and the presence mone therapy targeting the estrogen receptor (ER) pathway of poor-prognosis features such as high grade, and aggressive and targeted therapies directed against oncogenic proteins molecular subtypes (triple-negative (TN), basal, HER2- (HER2, EGFR, VEGF, PI3K/AKT/mTOR pathway, enriched). Early phase clinical trials using PD-1 or PD-L1 CDK4/6). Many other drugs are under development. inhibitors alone or in combination have shown objective http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Oncology Reports Springer Journals

Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1

Loading next page...
 
/lp/springer_journal/immunotherapy-in-breast-cancer-the-emerging-role-of-pd-1-and-pd-l1-qk9hpLBwr9
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Oncology
ISSN
1523-3790
eISSN
1534-6269
D.O.I.
10.1007/s11912-017-0627-0
Publisher site
See Article on Publisher Site

Abstract

Curr Oncol Rep (2017) 19:64 DOI 10.1007/s11912-017-0627-0 BREAST CANCER (B OVERMOYER, SECTION EDITOR) Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1 1,2,3 1,2,3 François Bertucci & Anthony Gonçalves Springer Science+Business Media, LLC 2017 Abstract Introduction Purpose of Review The purpose of the review is to summarize the data regarding PD-L1 expression in breast cancer and the Despite considerable progresses over the past three decades, results of first clinical trials with PD-1 or PD-L1 inhibitors in 15% of patients with breast cancer still develop metastases patients with metastatic breast cancer. and die. Improved understanding of mammary oncogenesis Recent Findings PD-L1 expression is heterogeneous across has led to major therapeutic advances with the approval of primary breast cancers, and is generally associated with the several drugs targeting cancer cells. Examples include hor- presence of tumor-infiltrating lymphocytes and the presence mone therapy targeting the estrogen receptor (ER) pathway of poor-prognosis features such as high grade, and aggressive and targeted therapies directed against oncogenic proteins molecular subtypes (triple-negative (TN), basal, HER2- (HER2, EGFR, VEGF, PI3K/AKT/mTOR pathway, enriched). Early phase clinical trials using PD-1 or PD-L1 CDK4/6). Many other drugs are under development. inhibitors alone or in combination have shown objective

Journal

Current Oncology ReportsSpringer Journals

Published: Aug 10, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off